vismodegib,

Nicole Remmert1, Lauren Dixon1, Jay Truitt2

  • 1School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.

Proceedings (Baylor University. Medical Center)
|February 24, 2025
PubMed
概括

在基底细胞癌 (BCC) 患者中,vismodegib治疗导致异常的组织学变化. 该药物可能会改变BCC的典型外观和免疫标记,这是一个罕见的现象.